Novel blood-based hypomethylation of SH3BP5 is associated with very early-stage lung adenocarcinoma.
Rong QiaoRunbo ZhongChunlan LiuFeifei DiZheng ZhangLing WangTian XuYue WangLiping DaiWanjian GuBaohui HanRongxi YangPublished in: Genes & genomics (2021)
Our study revealed an association between blood-based SH3BP5 hypomethylation and very early-stage LUAD, which provides a novel support for the blood-based methylation signatures as a potential marker for the evaluation of cancer risk.